While high doses of estrogen, in combination with androgens, can initiate prostate cancer (PCa) via activation of the estrogen receptor α (ERα), the role of ERα in PCa cells within established tumors is largely unknown. Here we show that expression of ERα is increased in high grade human PCa. Similarly, ERα is elevated in mouse models of aggressive PCa driven by MYC overexpression or deletion of PTEN. Within the prostate of PTEN-deficient mice, there is a progressive pattern of ERα expression: low in benign glands, moderate in tumors within the dorsal, lateral and ventral lobes, and high in tumors within the anterior prostate. This expression significantly correlates with the proliferation marker Ki67. Furthermore, in vitro knockdown of ERα...
The role of ERbeta in prostate cancer is unclear, although loss of ERbeta is associated with aggress...
Abstract Background For every six men, one will be diagnosed with prostate cancer (PCa) in their lif...
Prostate cancer (PCa) and benign prostatic hyperplasia (BPH) are androgen-dependent diseases commonl...
While high doses of estrogen, in combination with androgens, can initiate prostate cancer (PCa) via...
The role of ERβ in prostate cancer is unclear, although loss of ERβ is associated with aggressive di...
SummaryThe role of ERβ in prostate cancer is unclear, although loss of ERβ is associated with aggres...
Estrogen receptor β (ERβ) was first identified in the rodent prostate and is abundantly expressed in...
Estrogen receptor β (ERβ) was first identified in the rodent prostate and is abundantly expressed in...
High Gleason grade prostate cancers are aggressive. Currently, the major target for treatment is the...
The androgen receptor (AR) signaling pathway is one of the key pathways deregulated in prostate canc...
Prostate cancer (PCa) treatment was first established by Huggins and Hodges in 1941, primarily descr...
Recent studies indicate that estrogen-related receptors (ERRs) are involved in similar estrogen rece...
Prostate cancer (PC) is characterised by dependence upon androgen receptor (AR) as its driving oncog...
AbstractIn combination with androgens, estrogens can induce aberrant growth and malignancy of the pr...
The aim of this study was to identify the expression, cellular localization and regulation of classi...
The role of ERbeta in prostate cancer is unclear, although loss of ERbeta is associated with aggress...
Abstract Background For every six men, one will be diagnosed with prostate cancer (PCa) in their lif...
Prostate cancer (PCa) and benign prostatic hyperplasia (BPH) are androgen-dependent diseases commonl...
While high doses of estrogen, in combination with androgens, can initiate prostate cancer (PCa) via...
The role of ERβ in prostate cancer is unclear, although loss of ERβ is associated with aggressive di...
SummaryThe role of ERβ in prostate cancer is unclear, although loss of ERβ is associated with aggres...
Estrogen receptor β (ERβ) was first identified in the rodent prostate and is abundantly expressed in...
Estrogen receptor β (ERβ) was first identified in the rodent prostate and is abundantly expressed in...
High Gleason grade prostate cancers are aggressive. Currently, the major target for treatment is the...
The androgen receptor (AR) signaling pathway is one of the key pathways deregulated in prostate canc...
Prostate cancer (PCa) treatment was first established by Huggins and Hodges in 1941, primarily descr...
Recent studies indicate that estrogen-related receptors (ERRs) are involved in similar estrogen rece...
Prostate cancer (PC) is characterised by dependence upon androgen receptor (AR) as its driving oncog...
AbstractIn combination with androgens, estrogens can induce aberrant growth and malignancy of the pr...
The aim of this study was to identify the expression, cellular localization and regulation of classi...
The role of ERbeta in prostate cancer is unclear, although loss of ERbeta is associated with aggress...
Abstract Background For every six men, one will be diagnosed with prostate cancer (PCa) in their lif...
Prostate cancer (PCa) and benign prostatic hyperplasia (BPH) are androgen-dependent diseases commonl...